AstraZeneca Pharma Intrinsic Value
AstraZeneca Pharma (ASTRAZEN) median intrinsic value is ₹3202.20 from 9 valuation models (range ₹2402–₹7028), vs current price ₹8005.50 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse AstraZeneca Pharma ownership pattern to track promoter, FII and institutional holdings.
ASTRAZEN Valuation Methods Summary — DCF, Graham Number & P/E
AstraZeneca Pharma intrinsic value across 9 models vs current price ₹8005.50 — upside/downside and value range per method. Read ASTRAZEN dividend yield for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2401.65 | ₹1921.32 - ₹2881.98 | -70.0% | EPS: ₹46.30, Sector P/E: 22x |
| Book Value Method | asset | ₹3492.00 | ₹3142.80 - ₹3841.20 | -56.4% | Book Value/Share: ₹1746.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹7028.00 | ₹6325.20 - ₹7730.80 | -12.2% | Revenue/Share: ₹3514.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹5900.00 | ₹5310.00 - ₹6490.00 | -26.3% | EBITDA: ₹295.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3202.20 | ₹2561.76 - ₹3842.64 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2401.65 | ₹2161.49 - ₹2641.82 | -70.0% | EPS Growth: 5.6%, Fair P/E: 4.4x |
| Growth Adjusted P/E | growth | ₹2401.65 | ₹2161.49 - ₹2641.82 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹4002.75 | ₹3602.47 - ₹4403.03 | -50.0% | ROE: 13.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹2401.65 | ₹2161.49 - ₹2641.82 | -70.0% | EPS: ₹46.30, BVPS: ₹1746.00 |
ASTRAZEN Intrinsic Value vs Market Price — All Valuation Models
AstraZeneca Pharma fair value range ₹2402–₹7028 vs current market price ₹8005.50 across 9 valuation models. For current market price and key ratios, visit AstraZeneca Pharma share price screener.
ASTRAZEN Intrinsic Value Analysis — Undervalued or Overvalued?
AstraZeneca Pharma median intrinsic value ₹3202.20, current price ₹8005.50 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of ASTRAZEN?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of AstraZeneca Pharma (ASTRAZEN) is ₹3202.20 (median value). With the current market price of ₹8005.50, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹2401.65 to ₹7028.00, indicating ₹2401.65 - ₹7028.00.
Is ASTRAZEN undervalued or overvalued?
Based on our multi-method analysis, AstraZeneca Pharma (ASTRAZEN) appears to be trading above calculated value by approximately 60.0%.
ASTRAZEN Financial Health — Key Ratios vs Industry Benchmarks
AstraZeneca Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.89 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 15.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.88x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ASTRAZEN Cash Flow Quality — Operating & Free Cash Flow
AstraZeneca Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹65 Cr | ₹65 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹28 Cr | ₹28 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹58 Cr | ₹58 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹101 Cr | ₹101 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹105 Cr | ₹105 Cr | Positive Free Cash Flow | 8/10 |